CC
SNDX icon

Corton Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Corton Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$250K Sell
16,267
-1,589
-9% -$20.8K 0.62% 52
2025
Q2 		$167K Buy
+17,856
New +$197K 0.19% 267
2022
Q2 		– Sell
-16,925
Closed -$294K – 502
2022
Q1 		$294K Buy
+16,925
New +$285K 0.13% 242

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Corton Capital's SNDX Position: Q3 2025 in Review

Corton Capital reduced its Syndax Pharmaceuticals (SNDX) stake by 8.9% in Q3 2025, selling an estimated $20.8K and leaving 16,267 shares worth $250K. The position accounts for 0.62% of the portfolio, ranked #52.

Corton Capital first reported a position in SNDX in Q1 2022 and has held it in 3 quarters since. The position peaked at $294K in Q1 2022. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • Corton Capital held 16,267 shares of Syndax Pharmaceuticals worth $250K as of Q3 2025.
  • Corton Capital sold 1,589 Syndax Pharmaceuticals shares in Q3 2025, an estimated $20.8K.
  • Syndax Pharmaceuticals made up 0.62% of Corton Capital's portfolio in Q3 2025, its #52 holding.
  • Corton Capital first reported a position in Syndax Pharmaceuticals in Q1 2022 and has held it in 3 quarters since.
  • Corton Capital's Syndax Pharmaceuticals position peaked at $294K in Q1 2022.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.